PMID- 19464530
OWN - NLM
STAT- MEDLINE
DCOM- 20090721
LR  - 20171116
IS  - 0264-410X (Print)
IS  - 0264-410X (Linking)
VI  - 27
IP  - 27
DP  - 2009 Jun 2
TI  - Vaccination with human papillomavirus type 16-derived peptides using a tattoo 
      device.
PG  - 3519-29
LID - 10.1016/j.vaccine.2009.03.073 [doi]
AB  - Tattooing has been shown to be very efficient at inducing immunity by vaccination 
      with DNA vaccines. In this study, we examined the usability of tattooing for 
      delivery of peptide vaccines. We compared tattooing with subcutaneous (s.c.) 
      needle injection using peptides derived from human papillomavirus type 16 (HPV16) 
      proteins. We observed that higher peptide-specific immune responses were elicited 
      after vaccination with the simple peptides (E7(44-62) and E7(49-57)) and keyhole 
      limpet hemocyanin-(KLH)-conjugated peptides (E7(49-57), L2(18-38) and 
      L2(108-120)) with a tattoo device compared to s.c. inoculation. The 
      administration of the synthetic oligonucleotide containing immunostimulatory CpG 
      motifs (ODN1826) enhanced the immune responses developed after s.c. injection of 
      some peptides (E7(44-62), KLH-conjugated L2(18-38) and L2(108-120)) to levels 
      close to or even comparable to those after tattoo delivery of identical peptides 
      with ODN1826. The highest efficacy of tattooing was observed in combination with 
      ODN1826 for the vaccination with the less immunogenic E6(48-57) peptide and 
      KLH-conjugated and non-conjugated E7(49-57) peptides which form the visible 
      aggregates that could negatively influence the development of immune responses 
      after s.c. injection but probably not after tattooing. In summary, we first 
      evidenced that tattoo administration of peptide vaccines that might be useful in 
      some cases efficiently induced both humoral and cell-mediated immune responses.
FAU - Pokorna, Dana
AU  - Pokorna D
AD  - Institute of Hematology and Blood Transfusion, Department of Experimental 
      Virology, U Nemocnice 1, 12820 Prague 2, Czech Republic. danap@uhkt.cz
FAU - Polakova, Ingrid
AU  - Polakova I
FAU - Kindlova, Martina
AU  - Kindlova M
FAU - Duskova, Martina
AU  - Duskova M
FAU - Ludvikova, Viera
AU  - Ludvikova V
FAU - Gabriel, Pavel
AU  - Gabriel P
FAU - Kutinova, Lud'a
AU  - Kutinova L
FAU - Muller, Martin
AU  - Muller M
FAU - Smahel, Michal
AU  - Smahel M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090416
PL  - Netherlands
TA  - Vaccine
JT  - Vaccine
JID - 8406899
RN  - 0 (Capsid Proteins)
RN  - 0 (E6 protein, Human papillomavirus type 16)
RN  - 0 (L2 protein, Human papillomavirus type 16)
RN  - 0 (Oncogene Proteins, Viral)
RN  - 0 (Papillomavirus E7 Proteins)
RN  - 0 (Papillomavirus Vaccines)
RN  - 0 (Peptide Fragments)
RN  - 0 (Repressor Proteins)
RN  - 0 (Vaccines, DNA)
RN  - 0 (oncogene protein E7, Human papillomavirus type 16)
RN  - 9013-72-3 (Hemocyanins)
RN  - FV4Y0JO2CX (keyhole-limpet hemocyanin)
SB  - IM
MH  - Amino Acid Sequence
MH  - Animals
MH  - Capsid Proteins/*immunology
MH  - Female
MH  - Hemocyanins/immunology
MH  - Human papillomavirus 16/*immunology
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Molecular Sequence Data
MH  - Oncogene Proteins, Viral/*immunology
MH  - Papillomavirus E7 Proteins
MH  - Papillomavirus Vaccines/*immunology
MH  - Peptide Fragments/*immunology
MH  - Repressor Proteins/*immunology
MH  - T-Lymphocytes, Cytotoxic/immunology
MH  - Tattooing/*instrumentation
MH  - *Vaccination
MH  - Vaccines, DNA/immunology
EDAT- 2009/05/26 09:00
MHDA- 2009/07/22 09:00
CRDT- 2009/05/26 09:00
PHST- 2009/01/30 00:00 [received]
PHST- 2009/03/23 00:00 [revised]
PHST- 2009/03/24 00:00 [accepted]
PHST- 2009/05/26 09:00 [entrez]
PHST- 2009/05/26 09:00 [pubmed]
PHST- 2009/07/22 09:00 [medline]
AID - S0264-410X(09)00506-4 [pii]
AID - 10.1016/j.vaccine.2009.03.073 [doi]
PST - ppublish
SO  - Vaccine. 2009 Jun 2;27(27):3519-29. doi: 10.1016/j.vaccine.2009.03.073. Epub 2009 
      Apr 16.